---
document_datetime: 2025-12-02 05:11:49
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/axitinib-accord.html
document_name: axitinib-accord.html
version: success
processing_time: 0.1180136
conversion_datetime: 2025-12-28 09:49:05.637406
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Axitinib Accord

[RSS](/en/individual-human-medicine.xml/244575)

##### Authorised

This medicine is authorised for use in the European Union

axitinib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Axitinib Accord](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78199)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Axitinib Accord is used to treat adults with advanced renal cell carcinoma, a type of kidney cancer. 'Advanced' means that the cancer has started to spread. Axitinib Accord is used when treatment with a medicine containing sunitinib or with 'cytokines' (other cancer medicines) has failed.

Axitinib Accord contains the active substance axitinib and is a 'generic medicine'. This means that Axitinib Accord contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Axitinib Accord is Inlyta. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Axitinib Accord used?

Axitinib Accord can only be obtained with a prescription and treatment should be started by a doctor with experience in using cancer medicines.

Axitinib Accord is available as tablets to be taken twice a day. The dose can be adjusted according to the patient's response. It may be necessary to reduce the dose or interrupt treatment to manage certain side effects. In patients taking certain other medicines, the doctor may need to adjust the dose of Axitinib Accord.

Patients with moderately reduced liver function should receive a lower starting dose. Axitinib Accord should not be used in patients with severely reduced liver function.

For more information about using Axitinib Accord, see the package leaflet or contact your doctor or pharmacist.

## How does Axitinib Accord work?

The active substance in Axitinib Accord, axitinib, works by blocking some enzymes (proteins) known as tyrosine kinases that are found in vascular endothelial growth factor (VEGF) receptors on the surface of cancer cells. VEGF receptors are involved in the growth and spread of cancer cells and in the development of blood vessels that supply the tumours. By blocking these receptors, Axitinib Accord helps to reduce the growth and spread of the cancer and cut off the blood supply that keeps the cancer cells growing.

## How has Axitinib Accord been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Inlyta, and do not need to be repeated for Axitinib Accord.

As for every medicine, the company provided studies on the quality of Axitinib Accord. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Axitinib Accord?

Because Axitinib Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Axitinib Accord authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Axitinib Accord has been shown to have comparable quality and to be bioequivalent to Inlyta. Therefore, the Agency's view was that, as for Inlyta, the benefits of Axitinib Accord outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Axitinib Accord?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Axitinib Accord have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Inlyta also apply to Axitinib Accord, where appropriate.

As for all medicines, data on the use of Axitinib Accord are continuously monitored. Suspected side effects reported with Axitinib Accord are carefully evaluated and any necessary action taken to protect patients.

## Other information about Axitinib Accord

Axitinib Accord received a marketing authorisation valid throughout the EU on 19 September 2024.

Axitinib Accord : EPAR - Medicine overview

Reference Number: EMA/362300/2024

English (EN) (143.61 KB - PDF)

**First published:** 02/10/2024

[View](/en/documents/overview/axitinib-accord-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-357)

български (BG) (185.46 KB - PDF)

**First published:**

02/10/2024

[View](/bg/documents/overview/axitinib-accord-epar-medicine-overview_bg.pdf)

español (ES) (143.07 KB - PDF)

**First published:**

02/10/2024

[View](/es/documents/overview/axitinib-accord-epar-medicine-overview_es.pdf)

čeština (CS) (162.73 KB - PDF)

**First published:**

02/10/2024

[View](/cs/documents/overview/axitinib-accord-epar-medicine-overview_cs.pdf)

dansk (DA) (142.1 KB - PDF)

**First published:**

02/10/2024

[View](/da/documents/overview/axitinib-accord-epar-medicine-overview_da.pdf)

Deutsch (DE) (145.83 KB - PDF)

**First published:**

02/10/2024

[View](/de/documents/overview/axitinib-accord-epar-medicine-overview_de.pdf)

eesti keel (ET) (140.99 KB - PDF)

**First published:**

02/10/2024

[View](/et/documents/overview/axitinib-accord-epar-medicine-overview_et.pdf)

ελληνικά (EL) (163.94 KB - PDF)

**First published:**

02/10/2024

[View](/el/documents/overview/axitinib-accord-epar-medicine-overview_el.pdf)

français (FR) (143.63 KB - PDF)

**First published:**

02/10/2024

[View](/fr/documents/overview/axitinib-accord-epar-medicine-overview_fr.pdf)

hrvatski (HR) (163.07 KB - PDF)

**First published:**

02/10/2024

[View](/hr/documents/overview/axitinib-accord-epar-medicine-overview_hr.pdf)

italiano (IT) (142.17 KB - PDF)

**First published:**

02/10/2024

[View](/it/documents/overview/axitinib-accord-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (172.41 KB - PDF)

**First published:**

02/10/2024

[View](/lv/documents/overview/axitinib-accord-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (163.54 KB - PDF)

**First published:**

02/10/2024

[View](/lt/documents/overview/axitinib-accord-epar-medicine-overview_lt.pdf)

magyar (HU) (163.72 KB - PDF)

**First published:**

02/10/2024

[View](/hu/documents/overview/axitinib-accord-epar-medicine-overview_hu.pdf)

Malti (MT) (164.82 KB - PDF)

**First published:**

02/10/2024

[View](/mt/documents/overview/axitinib-accord-epar-medicine-overview_mt.pdf)

Nederlands (NL) (142.51 KB - PDF)

**First published:**

02/10/2024

[View](/nl/documents/overview/axitinib-accord-epar-medicine-overview_nl.pdf)

polski (PL) (165.67 KB - PDF)

**First published:**

02/10/2024

[View](/pl/documents/overview/axitinib-accord-epar-medicine-overview_pl.pdf)

português (PT) (143.94 KB - PDF)

**First published:**

02/10/2024

[View](/pt/documents/overview/axitinib-accord-epar-medicine-overview_pt.pdf)

română (RO) (161.09 KB - PDF)

**First published:**

02/10/2024

[View](/ro/documents/overview/axitinib-accord-epar-medicine-overview_ro.pdf)

slovenčina (SK) (162.95 KB - PDF)

**First published:**

02/10/2024

[View](/sk/documents/overview/axitinib-accord-epar-medicine-overview_sk.pdf)

slovenščina (SL) (162.77 KB - PDF)

**First published:**

02/10/2024

[View](/sl/documents/overview/axitinib-accord-epar-medicine-overview_sl.pdf)

Suomi (FI) (141.44 KB - PDF)

**First published:**

02/10/2024

[View](/fi/documents/overview/axitinib-accord-epar-medicine-overview_fi.pdf)

svenska (SV) (141.21 KB - PDF)

**First published:**

02/10/2024

[View](/sv/documents/overview/axitinib-accord-epar-medicine-overview_sv.pdf)

Axitinib Accord : EPAR - Risk management plan

English (EN) (215.62 KB - PDF)

**First published:** 02/10/2024

**Last updated:** 19/12/2024

[View](/en/documents/rmp/axitinib-accord-epar-risk-management-plan_en.pdf)

## Product information

Axitinib Accord : EPAR - Product information

English (EN) (580.41 KB - PDF)

**First published:** 02/10/2024

**Last updated:** 11/09/2025

[View](/en/documents/product-information/axitinib-accord-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-751)

български (BG) (1.03 MB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/bg/documents/product-information/axitinib-accord-epar-product-information_bg.pdf)

español (ES) (861.38 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/es/documents/product-information/axitinib-accord-epar-product-information_es.pdf)

čeština (CS) (701.46 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/cs/documents/product-information/axitinib-accord-epar-product-information_cs.pdf)

dansk (DA) (773.18 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/da/documents/product-information/axitinib-accord-epar-product-information_da.pdf)

Deutsch (DE) (872.87 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/de/documents/product-information/axitinib-accord-epar-product-information_de.pdf)

eesti keel (ET) (696.94 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/et/documents/product-information/axitinib-accord-epar-product-information_et.pdf)

ελληνικά (EL) (854.28 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/el/documents/product-information/axitinib-accord-epar-product-information_el.pdf)

français (FR) (788.92 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/fr/documents/product-information/axitinib-accord-epar-product-information_fr.pdf)

hrvatski (HR) (800.09 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/hr/documents/product-information/axitinib-accord-epar-product-information_hr.pdf)

íslenska (IS) (836.93 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/is/documents/product-information/axitinib-accord-epar-product-information_is.pdf)

italiano (IT) (808.17 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/it/documents/product-information/axitinib-accord-epar-product-information_it.pdf)

latviešu valoda (LV) (855.27 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/lv/documents/product-information/axitinib-accord-epar-product-information_lv.pdf)

lietuvių kalba (LT) (910.43 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/lt/documents/product-information/axitinib-accord-epar-product-information_lt.pdf)

magyar (HU) (833.52 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/hu/documents/product-information/axitinib-accord-epar-product-information_hu.pdf)

Malti (MT) (1.07 MB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/mt/documents/product-information/axitinib-accord-epar-product-information_mt.pdf)

Nederlands (NL) (722.91 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/nl/documents/product-information/axitinib-accord-epar-product-information_nl.pdf)

norsk (NO) (650.29 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/no/documents/product-information/axitinib-accord-epar-product-information_no.pdf)

polski (PL) (759.94 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/pl/documents/product-information/axitinib-accord-epar-product-information_pl.pdf)

português (PT) (864.22 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/pt/documents/product-information/axitinib-accord-epar-product-information_pt.pdf)

română (RO) (835.61 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/ro/documents/product-information/axitinib-accord-epar-product-information_ro.pdf)

slovenčina (SK) (709.99 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/sk/documents/product-information/axitinib-accord-epar-product-information_sk.pdf)

slovenščina (SL) (957.83 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/sl/documents/product-information/axitinib-accord-epar-product-information_sl.pdf)

Suomi (FI) (640.03 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/fi/documents/product-information/axitinib-accord-epar-product-information_fi.pdf)

svenska (SV) (756.62 KB - PDF)

**First published:**

02/10/2024

**Last updated:**

11/09/2025

[View](/sv/documents/product-information/axitinib-accord-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000293302 08/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Axitinib Accord : EPAR - All authorised presentations

English (EN) (87.48 KB - PDF)

**First published:** 02/10/2024

[View](/en/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-268)

български (BG) (94.9 KB - PDF)

**First published:**

02/10/2024

[View](/bg/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_bg.pdf)

español (ES) (91.82 KB - PDF)

**First published:**

02/10/2024

[View](/es/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_es.pdf)

čeština (CS) (91.19 KB - PDF)

**First published:**

02/10/2024

[View](/cs/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (89.89 KB - PDF)

**First published:**

02/10/2024

[View](/da/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (90.18 KB - PDF)

**First published:**

02/10/2024

[View](/de/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (88.58 KB - PDF)

**First published:**

02/10/2024

[View](/et/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (96.74 KB - PDF)

**First published:**

02/10/2024

[View](/el/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_el.pdf)

français (FR) (89.65 KB - PDF)

**First published:**

02/10/2024

[View](/fr/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (88.94 KB - PDF)

**First published:**

02/10/2024

[View](/hr/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (92.74 KB - PDF)

**First published:**

02/10/2024

[View](/is/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_is.pdf)

italiano (IT) (89.58 KB - PDF)

**First published:**

02/10/2024

[View](/it/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (90.95 KB - PDF)

**First published:**

02/10/2024

[View](/lv/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (91.66 KB - PDF)

**First published:**

02/10/2024

[View](/lt/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (93.81 KB - PDF)

**First published:**

02/10/2024

[View](/hu/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (91.85 KB - PDF)

**First published:**

02/10/2024

[View](/mt/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (88.16 KB - PDF)

**First published:**

02/10/2024

[View](/nl/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (89.8 KB - PDF)

**First published:**

02/10/2024

[View](/no/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_no.pdf)

polski (PL) (90.66 KB - PDF)

**First published:**

02/10/2024

[View](/pl/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_pl.pdf)

português (PT) (90.44 KB - PDF)

**First published:**

02/10/2024

[View](/pt/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_pt.pdf)

română (RO) (89.76 KB - PDF)

**First published:**

02/10/2024

[View](/ro/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (93.33 KB - PDF)

**First published:**

02/10/2024

[View](/sk/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (89.93 KB - PDF)

**First published:**

02/10/2024

[View](/sl/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (89.35 KB - PDF)

**First published:**

02/10/2024

[View](/fi/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (88.71 KB - PDF)

**First published:**

02/10/2024

[View](/sv/documents/all-authorised-presentations/axitinib-accord-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Axitinib Accord Active substance axitinib International non-proprietary name (INN) or common name axitinib Therapeutic area (MeSH) Carcinoma, Renal Cell Anatomical therapeutic chemical (ATC) code L01EK01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Axitinib Accord is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.

## Authorisation details

EMA product number EMEA/H/C/006206

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 25/07/2024 Marketing authorisation issued 19/09/2024 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Axitinib Accord : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (134.88 KB - PDF)

**First published:** 22/07/2025

**Last updated:** 11/09/2025

[View](/en/documents/procedural-steps-after/axitinib-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Axitinib Accord : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (138.45 KB - PDF)

**First published:** 19/12/2024

**Last updated:** 22/07/2025

[View](/en/documents/procedural-steps-after/axitinib-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Axitinib Accord : EPAR - Public assessment report

Adopted

Reference Number: EMA/372021/2024

English (EN) (929.38 KB - PDF)

**First published:** 02/10/2024

[View](/en/documents/assessment-report/axitinib-accord-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Axitinib Accord

Adopted

Reference Number: EMA/284159/2024

English (EN) (121.92 KB - PDF)

**First published:** 26/07/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-axitinib-accord_en.pdf)

#### News on Axitinib Accord

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024) 26/07/2024

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Axitinib Accord : EPAR - Product information - tracked changes

English (EN) (296.03 KB - DOCX)

**First published:** 22/07/2025

[View](/en/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-626)

български (BG) (366.71 KB - DOCX)

**First published:**

22/07/2025

[View](/bg/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_bg.docx)

español (ES) (505.87 KB - DOCX)

**First published:**

22/07/2025

[View](/es/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_es.docx)

čeština (CS) (217.16 KB - DOCX)

**First published:**

22/07/2025

[View](/cs/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (385.45 KB - DOCX)

**First published:**

22/07/2025

[View](/da/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (408.61 KB - DOCX)

**First published:**

22/07/2025

[View](/de/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (301.39 KB - DOCX)

**First published:**

22/07/2025

[View](/et/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (454.42 KB - DOCX)

**First published:**

22/07/2025

[View](/el/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_el.docx)

français (FR) (373.14 KB - DOCX)

**First published:**

22/07/2025

[View](/fr/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (401.35 KB - DOCX)

**First published:**

22/07/2025

[View](/hr/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (412.02 KB - DOCX)

**First published:**

22/07/2025

[View](/is/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_is.docx)

italiano (IT) (590.25 KB - DOCX)

**First published:**

22/07/2025

[View](/it/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (305.72 KB - DOCX)

**First published:**

22/07/2025

[View](/lv/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (555.02 KB - DOCX)

**First published:**

22/07/2025

[View](/lt/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (348.11 KB - DOCX)

**First published:**

22/07/2025

[View](/hu/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (458.49 KB - DOCX)

**First published:**

22/07/2025

[View](/mt/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (333.28 KB - DOCX)

**First published:**

22/07/2025

[View](/nl/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (205.52 KB - DOCX)

**First published:**

22/07/2025

[View](/no/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_no.docx)

polski (PL) (379.98 KB - DOCX)

**First published:**

22/07/2025

[View](/pl/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_pl.docx)

português (PT) (550.45 KB - DOCX)

**First published:**

22/07/2025

[View](/pt/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_pt.docx)

română (RO) (412.38 KB - DOCX)

**First published:**

22/07/2025

[View](/ro/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (380.67 KB - DOCX)

**First published:**

22/07/2025

[View](/sk/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (520.5 KB - DOCX)

**First published:**

22/07/2025

[View](/sl/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (253.41 KB - DOCX)

**First published:**

22/07/2025

[View](/fi/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (254.7 KB - DOCX)

**First published:**

22/07/2025

[View](/sv/documents/product-information-tracked-changes/axitinib-accord-epar-product-information-tracked-changes_sv.docx)

**This page was last updated on** 11/09/2025

## Share this page

[Back to top](#main-content)